Sarepta Therapeutics' (SRPT) Elevidys is put under a "little" pressure on Regenxbio's (RGNX) positive trial data in Duchenne muscular dystrophy, Wedbush Securities said in a note Friday.

The note pointed to statistically significant correlation between microdystrophin expression and functional improvement in the trial of RGX-202, and should benefit all microdystrophin gene therapy programs/products.

"We see no other big impact on Elevidys," it said. "We do not believe that the relatively small patient number in RGNX's study allows for a fair comparison of microdystrophin expression."

The report also said the regulatory pathway for RGX-202 remains to be defined.

Wedbush kept its outperform rating and a $35 price target.

Price: 18.12, Change: -0.56, Percent Change: -3.00